TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35766954
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (ILI) 1.5 mg/kg as a bolus followed by 1.5 mg/kg/h until the end of surgery (Group L)
Study: 34155070
Drug: Guided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided daily multidisciplinary rounds (DMRs) supported by a remote specialist and audit/feedback on care performance
Study: 35712635
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed cow’s milk protein formula (PHF, 75% carbohydrate as lactose; 12 mg Mg/100 kcal)
Study: 32384437
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) - a single 1-mL dose of betamethasone sodium plus 0.5 mL of prilocaine under ultrasound guidance (n=40)
Study: 39248249
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin
Study: 36326260
Drug: Abdomen infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdomen infusion site
Study: 34657218
Drug: Dapivirine gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine gel
Study: 34994269
Drug: Triple Pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Pill
Study: 34387964
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU)
Study: 32561160
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (iGlar)
Study: 35138767
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with medical care
Study: 33750471
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy targeting Type 2 inflammatory pathway (e.g., IL-4, IL-5, IL-13, IL-5R, IL-33, IgE)
Study: 35589771
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT, n=10)
Study: 32311780
Drug: Pegfilgrastim (PEG)
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim (PEG) 6 mg
Study: 35939559
Drug: ESO 20
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO 20 mg plus AMX 750 mg, Qid for 14 days (Group A)
Study: 32575945
Drug: Targeted artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted artery perfusion of verapamil and chemotherapy drugs
Study: 32575945
Drug: Targeted artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted artery perfusion of chemotherapy drugs alone (Control)
Study: 35311446
Drug: Multi-fiber bread
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-fiber bread (150 g daily, enriched with a 7-dietary fiber mixture providing 16.05 g of fibers)
Study: 39137016
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control
Study: 33359589
Drug: PTAH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTAH treatment beyond 1 year
Study: 35380374
Drug: ON-SXB 9
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON-SXB 9 g
Study: 32320024
Drug: Moderate-dose fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose fiber (7 g/d)
Study: 34882076
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 1)
Study: 32072735
Drug: Glimepiride plus
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride plus metformin
Study: 32462483
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surfactant therapy (MIST)
Study: 34003586
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs
Study: 39637881
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg
Study: 33693813
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplements
Study: 39247962
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT)
Study: 36512175
Drug: Abrocitinib 200
Normalized name: abrocitinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 200 mg once daily
Study: 34493431
Drug: TAS-115 200
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-115 200 mg/d
Study: 34430972
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day
Study: 33350678
Drug: Single-agent second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent second-line therapy
Study: 35426830
Drug: Bevacizumab 2.5
Normalized name: Bevacizumab 2.5 MG/0.1 ML Intraocular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 2.5 mg/kg administered as a one-time targeted intra-arterial infusion after blood-brain barrier disruption (BBBD)
Study: 33186325
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg per day
Study: 36401445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sodium lactate Ringer's solution)
Study: 32220910
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate
Study: 32037254
Drug: High Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Lp(a) group (Lp(a) >20 mg/dl)
Study: 32568196
Drug: Crenezumab 120
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Crenezumab 120 mg/kg intravenously every 4 weeks for 13 weeks
Study: 32568196
Drug: Crenezumab during
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Crenezumab during open-label extension (OLE) at originally assigned dose level, except for Cohort 3 (crenezumab 60 mg/kg during OLE)
Study: 34968756
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg
Study: 33332813
Drug: Systemic medications
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic medications (including cholinesterase inhibitor, ACE inhibitors, calcium channel blockers, beta‐blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein‐coupled receptors)
Study: 32319465
Drug: Juice enriched
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice enriched with highly polymerized inulin (12 g per 300 mL)
Study: 33707267
Drug: Pleuran oral
Normalized name: PLEURAL DRAINAGE KIT ROCKET #51411
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleuran oral suspension
Study: 32062048
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of twice-weekly rifapentine plus isoniazid (group B)
Study: 32033579
Drug: Gradual dose
Normalized name: MEDICINE DOSE CUP GRADUATED 30ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual dose reduction till eventual discontinuation of antipsychotics according to a tapering schedule
Study: 32873290
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day for 3 days
Study: 34225517
Drug: MDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT treatment
Study: 35238614
Drug: Phlebotomy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy group (500 mL bloodletting at baseline and after 6 weeks)
Study: 33934070
Drug: Tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab monotherapy (TCZm)
Study: 33982141
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) 24 IU twice daily for 4 weeks
Study: 34897499
Drug: Abatacept +
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept + MTX >8 mg/week
Study: 33384827
Drug: Fixed oral
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed oral appliance (OA)
Study: 32247714
Drug: Intermittent enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent enteral feeding (six 4-hourly feeds per 24 h, n = 62)
Study: 34383534
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylphenidate (0.6 mg/kg/dose)
Study: 36038001
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of a balanced mixture of amino acids (2 g/kg ideal body weight/day)
Study: 36038001
Drug: Placebo (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (balanced crystalloid solution)
Study: 35553047
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg
Study: 37928925
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group).
Study: 37722559
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT)
Study: 36056362
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy (4 sessions of 90 minutes each, divided over two half-days)
Study: 38061553
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy
Study: 36097258
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin
Study: 33590471
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) monotherapy
Study: 32943115
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (0.1 ml of resuspended BCG vaccine administered intradermally)
Study: 32502940
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NaCT)
Study: 36638112
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day
Study: 38715179
Drug: Dulaglutide 0.75
Normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.75 mg
Study: 32801202
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron as ferrous sulfate
Study: 38735015
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH)
Study: 32112555
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) combined with Skin-to-Skin Care (SSC)
Study: 39747681
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg
Study: 616877161
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + memantine (5 mg/day)
Study: 34326035
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment for NMZL
Study: 34528669
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment Group (targeted SBP <120 mm Hg)
Study: 33742207
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU monthly)
Study: 36507215
Drug: Riluzole administration
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole administration (group A)
Study: 35943883
Drug: Riboflavin 100
Normalized name: riboflavin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 100 mg/d
Study: 35943883
Drug: Combined Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Riboflavin 50 and 100 mg/d
Study: 36227672
Drug: Oral montmorillonite
Normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montmorillonite powder
Study: 33711179
Drug: Nemolizumab 30
Normalized name: Nemolizumab 30 mg in 100 mg SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [NEMLUVIO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 30 mg
Study: 33612360
Drug: Ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric derisomaltose 20 mg/kg
Study: 35034502
Drug: Second novel
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second novel hormone therapy (NHT)
Study: 32951715
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg daily, 1 hour before bedtime for 12 weeks
Study: 35120408
Drug: Restorative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative treatment (RT)
Study: 32049319
Drug: Dose Reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Reduction (DR)
Study: 32271718
Drug: Exebacase +
Normalized name: Exebacase
DrugBank: Exebacase (DB16161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exebacase + antibiotics (MRSA patients)
Study: 34120773
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg once daily
Study: 35148753
Drug: Previous psychological
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous psychological treatment for PMDD
Study: 36384181
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) in seven weekly sessions for eight weeks
Study: 36123649
Drug: Home Treatment
Normalized name: Home-brew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Treatment with Peer Support (HT + PS)
Study: 32807158
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multi-acupoints
Study: 34389292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin).
Study: 33985457
Drug: Surgical glove
Normalized name: Astrapro Surgical Gloves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical glove compression therapy (two one-size-smaller gloves on one hand)
Study: 36050514
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine in SARDs patients
Study: 36050514
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine in control group
Study: 35771533
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy
Study: 34702183
Drug: Erector Spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector Spinae Plane block (ESPB) with 40 ml of 0.5% Ropivacaine, divided into two equal volumes, injected at T8 level under ultrasound guidance.
Study: 36593070
Drug: Ibrutinib monotherapy
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib monotherapy
Study: 32084218
Drug: Tyrosine administration
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine administration
Study: 34910312
Drug: Odiparcil 500
Normalized name: Odiparcil
DrugBank: Odiparcil (DB06609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odiparcil 500 mg twice daily
Study: 33285343
Drug: Intravenous meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meglumine antimoniate (IV‐MA) administered via intravenous injections at a dosage of 10–20 mg Sb5+/kg/day for 20 days.
Study: 39461860
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy
Study: 34969608
Drug: Mebeverine capsule
Normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine capsule
Study: 34032758
Drug: Patient Engagement
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Engagement and Medication Safety Management (PE‐MSM) program
Study: 32342893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 165° backrest angle with a seat pan of 20°
Study: 34352069
Drug: filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgotinib 200 mg once daily for 12 weeks
Study: 36094537
Drug: Real-time prescription
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time prescription benefit recommendations
Study: 34161745
Drug: Nitrate supplement
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplement (0.11 mmol nitrate/kg as beetroot juice)
Study: 32842203
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor combined with ranitidine
Study: 35792253
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) on the tongue surface
Study: 33558662
Drug: Cryotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy + GM-CSF (Treatment group)
Study: 33384335
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment - exclusive enteral nutrition (EEN) or oral prednisolone (1 mg/kg, max 40 mg)
Study: 34787952
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of d‐β‐hydroxybutyrate (βHB) in the form of a KE drink (ΔG®) with 2 g of L‐alanine
Study: 34054112
Drug: lumateperone 42
Normalized name: lumateperone 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumateperone 42 mg
Study: 38546622
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT)
Study: 34615779
Drug: Intralesional infiltration
Normalized name: CD8+ enriched young tumor infiltrating lymphocytes
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional infiltration of 2 mL dexamethasone (4 mg/mL) + hyaluronidase 1500 IU dissolved in 0.5 mL of 2% lignocaine twice a week for 3 months
Study: 35553047
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg
Study: 32895281
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (target Hb levels of 100-120 g/L)
Study: 36107424
Drug: Weekly participation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly participation rates
Study: 35011752
Drug: Pharmacopuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopuncture therapy
Study: 39499309
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg
Study: 33347632
Drug: Anti-CGRP monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CGRP monoclonal antibodies
Study: 33068343
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with basic treatment of internal medicine and rehabilitation training
Study: 36378691
Drug: Dual-therapy CD34
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS)
Study: 34127624
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy alone for 3 weeks